Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 10—October 2016
Synopsis

Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes

David MesherComments to Author , Kate Soldan, Matti Lehtinen, Simon Beddows, Marc Brisson, Julia M.L. Brotherton, Eric P.F. Chow, Teresa Cummings, Mélanie Drolet, Christopher K. Fairley, Suzanne M. Garland, Jessica A. Kahn, Kimberley Kavanagh, Lauri E. Markowitz, Kevin G. Pollock, Anna Söderlund-Strand, Pam Sonnenberg, Sepehr N. Tabrizi, Clare Tanton, Elizabeth R. Unger, and Sara L. Thomas
Author affiliations: Public Health England, London, UK (D. Mesher, K. Soldan, S. Beddows); London School of Hygiene and Tropical Medicine, London (D. Mesher, S.L. Thomas); University of Tampere, Tampere, Finland (M. Lehtinen); Imperial College London, London (M. Brisson); Centre de recherche du CHU de Québec, Quebec City, Quebec, Canada (M. Brisson, M. Drolet); Université Laval, Quebec (M. Brisson, M Drolet); Victorian Cytology Service, Melbourne, Victoria, Australia (J.M.L. Brotherton); University of Melbourne, Melbourne (J.M.L. Brotherton, S.M. Garland, S.N. Tabrizi); Melbourne Sexual Health Centre, Melbourne (E.P.F. Chow, C.K. Fairley); Monash University, Melbourne (E.P.F. Chow, C.K. Fairley); Indiana University School of Medicine, Indianapolis, Indiana, USA (T. Cummings); Murdoch Childrens Research Institute, Parkville, Victoria, Australia (S.M. Garland, S.N. Tabrizi); The Royal Women’s Hospital, Melbourne (S.M. Garland, S.N. Tabrizi); Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA (J.A. Kahn); University of Cincinnati College of Medicine, Cincinnati (J.A. Kahn); University of Strathclyde, Glasgow, Scotland, UK (K. Kavanagh); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (L. Markowitz, E. Unger); Health Protection Scotland, Glasgow (K.G. Pollock); Division of Clinical Microbiology, Laboratory Medicine, Skåne, Lund, Sweden (A. Söderlund-Strand); University College London, London (P. Sonnenberg, C. Tanton)

Main Article

Figure 3

Prevalence ratios and 95% CIs for other high-risk human papillomavirus (HPV) types (HPV52 and HPV58) included in the nonavalent vaccine for girls and women <19 years of age and women 20–24 years of age in studies included in a meta-analysis of changes in prevalences of nonvaccine HPV genotypes after introduction of HPV vaccination. A) HPV52; B) HPV58. Percentages in brackets represent vaccination coverage (>1 dose) for each study and age group. The sizes of the gray boxes around the plot p

Figure 3. Prevalence ratios and 95% CIs for other high-risk human papillomavirus (HPV) types (HPV52 and HPV58) included in the nonavalent vaccine for girls and women <19 years of age and women 20–24 years of age in studies included in a meta-analysis of changes in prevalences of nonvaccine HPV genotypes after introduction of HPV vaccination. A) HPV52; B) HPV58. Percentages in brackets represent vaccination coverage (>1 dose) for each study and age group. The sizes of the gray boxes around the plot points indicates the relative weight given to each study in the calculation of the summary estimate. The study by Cameron et al. (25) is omitted from analyses for the younger age group because this study included no data for persons <19 years of age. The study by Cummings et al. (21) is omitted from analyses for women 20–24 years of age because the study included no data for this age group. Pre, prevaccination; post, postvaccination.

Main Article

References
  1. Walboomers  JM, Jacobs  MV, Manos  MM, Bosch  FX, Kummer  JA, Shah  KV, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.DOIPubMedGoogle Scholar
  2. de Sanjose  S, Quint  WG, Alemany  L, Geraets  DT, Klaustermeier  JE, Lloveras  B, ; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–56.DOIPubMedGoogle Scholar
  3. Li  N, Franceschi  S, Howell-Jones  R, Snijders  PJ, Clifford  GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128:927–35.DOIPubMedGoogle Scholar
  4. Mesher  D, Cuschieri  K, Hibbitts  S, Jamison  J, Sargent  A, Pollock  KG, Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation. J Clin Pathol. 2015;68:135–40.DOIPubMedGoogle Scholar
  5. Ault  KA; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369:1861–8.DOIPubMedGoogle Scholar
  6. Lehtinen  M, Paavonen  J, Wheeler  CM, Jaisamrarn  U, Garland  SM, Castellsagué  X, ; HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:89–99. DOIPubMedGoogle Scholar
  7. Joura  EA, Giuliano  AR, Iversen  OE, Bouchard  C, Mao  C, Mehlsen  J, ; Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711–23.DOIPubMedGoogle Scholar
  8. Brown  DR, Kjaer  SK, Sigurdsson  K, Iversen  OE, Hernandez-Avila  M, Wheeler  CM, The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199:926–35.DOIPubMedGoogle Scholar
  9. Wheeler  CM, Castellsagué  X, Garland  SM, Szarewski  A, Paavonen  J, Naud  P, ; HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:100–10. DOIPubMedGoogle Scholar
  10. Cervical Cancer Action. Global maps. Global progress in HPV vaccination. 2014 Sep [cited 2016 Apr 22]. http://www.cervicalcanceraction.org/comments/comments3.php
  11. Drolet  M, Bénard  É, Boily  MC, Ali  H, Baandrup  L, Bauer  H, Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15:565–80.DOIPubMedGoogle Scholar
  12. Palmroth  J, Merikukka  M, Paavonen  J, Apter  D, Eriksson  T, Natunen  K, Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination. Int J Cancer. 2012;131:2832–8.DOIPubMedGoogle Scholar
  13. Malagón  T, Drolet  M, Boily  MC, Franco  EL, Jit  M, Brisson  J, Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:781–9.DOIPubMedGoogle Scholar
  14. Bouvard  V, Baan  R, Straif  K, Grosse  Y, Secretan  B, El Ghissassi  F, ; WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens—Part B: biological agents. Lancet Oncol. 2009;10:321–2.DOIPubMedGoogle Scholar
  15. Liberati  A, Altman  DG, Tetzlaff  J, Mulrow  C, Gøtzsche  PC, Ioannidis  JP, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.DOIPubMedGoogle Scholar
  16. Mesher  D, Panwar  K, Thomas  SL, Beddows  S, Soldan  K. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. BMJ Open. 2016;6:e009915.DOIPubMedGoogle Scholar
  17. Söderlund-Strand  A, Uhnoo  I, Dillner  J. Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study. Cancer Epidemiol Biomarkers Prev. 2014;23:2757–64.DOIPubMedGoogle Scholar
  18. Higgins  JP, Thompson  SG, Deeks  JJ, Altman  DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.DOIPubMedGoogle Scholar
  19. Bissett  SL, Howell-Jones  R, Swift  C, De Silva  N, Biscornet  L, Parry  JV, Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males. J Med Virol. 2011;83:1744–51.DOIPubMedGoogle Scholar
  20. Dunne  EF, Naleway  A, Smith  N, Crane  B, Weinmann  S, Braxton  J, Reduction in human papillomavirus vaccine type prevalence among young women screened for cervical cancer in an integrated US healthcare delivery system in 2007 and 2012–2013. J Infect Dis. 2015;212:1970–5.DOIPubMedGoogle Scholar
  21. Cummings  T, Zimet  GD, Brown  D, Tu  W, Yang  Z, Fortenberry  JD, Reduction of HPV infections through vaccination among at-risk urban adolescents. Vaccine. 2012;30:5496–9.DOIPubMedGoogle Scholar
  22. Kahn  JA, Brown  DR, Ding  L, Widdice  LE, Shew  ML, Glynn  S, Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics. 2012;130:e249–56.DOIPubMedGoogle Scholar
  23. Sonnenberg  P, Clifton  S, Beddows  S, Field  N, Soldan  K, Tanton  C, Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet. 2013;382:1795–806.DOIPubMedGoogle Scholar
  24. Tabrizi  SN, Brotherton  JM, Kaldor  JM, Skinner  SR, Liu  B, Bateson  D, Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014;14:958–66.DOIPubMedGoogle Scholar
  25. Cameron  RL, Kavanagh  K, Pan  J, Love  J, Cuschieri  K, Robertson  C, Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009–2013. Emerg Infect Dis. 2016;22:56–64.DOIPubMedGoogle Scholar
  26. Markowitz  LE, Liu  G, Hariri  S, Steinau  M, Dunne  EF, Unger  ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137:e20151968.DOIPubMedGoogle Scholar
  27. Chow  EP, Danielewski  JA, Fehler  G, Tabrizi  SN, Law  MG, Bradshaw  CS, Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Lancet Infect Dis. 2015;15:1314–23.DOIPubMedGoogle Scholar
  28. Public Health England. Sexually transmitted infections (STIs): annual data tables. 2015 Jun 23 [cited 2016 Apr 22]. https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-annual-data-tables
  29. Ali  H, Donovan  B, Wand  H, Read  TR, Regan  DG, Grulich  AE, Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032.DOIPubMedGoogle Scholar
  30. Chow  EP, Read  TR, Wigan  R, Donovan  B, Chen  MY, Bradshaw  CS, Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2015;91:214–9.DOIPubMedGoogle Scholar
  31. Howell-Jones  R, Soldan  K, Wetten  S, Mesher  D, Williams  T, Gill  ON, Declining genital Warts in young women in england associated with HPV 16/18 vaccination: an ecological study. J Infect Dis. 2013;208:1397–403.DOIPubMedGoogle Scholar
  32. Lehtinen  M, Kaasila  M, Pasanen  K, Patama  T, Palmroth  J, Laukkanen  P, Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. Int J Cancer. 2006;119:2612–9.DOIPubMedGoogle Scholar
  33. Laukkanen  P, Koskela  P, Pukkala  E, Dillner  J, Läärä  E, Knekt  P, Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol. 2003;84:2105–9.DOIPubMedGoogle Scholar
  34. Bruni  L, Diaz  M, Castellsagué  X, Ferrer  E, Bosch  FX, de Sanjosé  S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202:1789–99.DOIPubMedGoogle Scholar
  35. Tota  JE, Ramanakumar  AV, Villa  LL, Richardson  H, Burchell  AN, Koushik  A, Evaluation of human papillomavirus type replacement postvaccination must account for diagnostic artifacts: masking of HPV52 by HPV16 in anogenital specimens. Cancer Epidemiol Biomarkers Prev. 2015;24:286–90.DOIPubMedGoogle Scholar
  36. Cornall  AM, Phillips  S, Cummins  E, Garland  SM, Tabrizi  SN. In vitro assessment of the effect of vaccine-targeted human papillomavirus (HPV) depletion on detection of non-vaccine HPV types: implications for post-vaccine surveillance studies. J Virol Methods. 2015;214:10–4.DOIPubMedGoogle Scholar
  37. Higgins  JPT, Green  S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 [cited 2016 Apr 22]. http://handbook.cochrane.org/
  38. Tota  JE, Ramanakumar  AV, Jiang  M, Dillner  J, Walter  SD, Kaufman  JS, Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol. 2013;178:625–34.DOIPubMedGoogle Scholar
  39. Safaeian  M, Rodriguez  AC. Invited commentary: multiple human papillomavirus infections and type replacement-anticipating the future after human papillomavirus vaccination. Am J Epidemiol. 2014;180:1076–81.DOIPubMedGoogle Scholar

Main Article

Page created: September 20, 2016
Page updated: September 20, 2016
Page reviewed: September 20, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external